Dr. John Nutt
Add to your Care-Team
Dr. John Nutt
Dr. John Nutt
I specialize in
My answers and insights have
Helped 20 people
Here are kind words from others
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I am located at
3181 S W Sam Jackson Park Rd
Portland , OR 97201
3181 SW Sam Jackson Park Rd
Portland , OR 97239
Accepted Insurance Plans
I was educated and trained at
Medical / Graduate School
Baylor College of Medicine
Baylor College of Medicine
MS - Master of Science
Dr. John Nutt M
I've won the following awards
Top Doctors, Portland Monthly Magazine
Movement Disorders Research Award, American Academy of Neurology
Best Doctor, Best Doctors in AmericaBest Doctor
Top Doctors, Portland Monthly Magazine
Authors' Response to Marras & Oakes "Piecing together the puzzle of progression and mortality in Parkinson's disease"
Br J Clin Pharmacol., Sep (2012)
Postural sway as a marker of progression in Parkinson's disease: a pilot longitudinal study.
Gait Posture., Jul;36(3):471-6 (2012)
Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.
Mov. Disord., May;27(6):750-3 (2012)
Peering through the FoG: visual manipulations shed light on freezing of gait.
Mov. Disord., Apr;27(4):470-2 (2012)
Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.
Br J Clin Pharmacol., Aug;74(2):284-95 (2012)
Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.
Br J Clin Pharmacol., Aug;74(2):267-83 (2012)
Freezing of gait is associated with a mismatch between motor imagery and motor execution in narrow doorways, not with failure to judge doorway passability.
Neuropsychologia., Dec;49(14):3981-8 (2011)
Freezing of gait: moving forward on a mysterious clinical phenomenon.
Lancet Neurol., Aug;10(8):734-44 (2011)
Trunk accelerometry reveals postural instability in untreated Parkinson's disease.
Parkinsonism Relat. Disord., Aug;17(7):557-62 (2011)
Milestones in gait, balance, and falling.
Mov. Disord., May;26(6):1166-74 (2011)
Errors in postural preparation lead to increased choice reaction times for step initiation in older adults.
J. Gerontol. A Biol. Sci. Med. Sci., Jun;66(6):705-13 (2011)
"Silly walks" in Parkinson's disease: unusual presentation of dopaminergic-induced dyskinesias.
Mov. Disord., Aug;26(9):1782-4 (2011)
Interpreting the results of Parkinson's disease clinical trials: time for a change.
Mov. Disord., Mar;26(4):569-77 (2011)
Parkinson disease: deep brain stimulation versus best medical therapy for PD.
Nat Rev Neurol., Oct;6(10):530-2 (2010)
A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD.
Neurology., Oct;75(14):1292-9 (2010)
Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease.
Neurology., Oct;75(14):1263-9 (2010)
Assessing mobility at home in people with early Parkinson's disease using an instrumented Timed Up and Go test.
Parkinsonism Relat. Disord., May;17(4):277-80 (2011)
Preparation for compensatory forward stepping in Parkinson's disease.
Arch Phys Med Rehabil., Sep;91(9):1332-8 (2010)
Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.
Mov. Disord., Oct;25(13):2156-63 (2010)
A novel X-linked four-repeat tauopathy with Parkinsonism and spasticity.
Mov. Disord., Jul;25(10):1409-17 (2010)
Piloting the NPF data-driven quality improvement initiative.
Parkinsonism Relat. Disord., Sep;16(8):517-21 (2010)
iTUG, a sensitive and reliable measure of mobility.
IEEE Trans Neural Syst Rehabil Eng., Jun;18(3):303-10 (2010)
Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.
Neurology., Apr;74(15):1191-7 (2010)
Objective measurement of dyskinesia in Parkinson's disease using a force plate.
Mov. Disord., Apr;25(5):602-8 (2010)
Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.
Arch. Neurol., Jan;67(1):27-32 (2010)
Analyzing 180 degrees turns using an inertial system reveals early signs of progression of Parkinson's disease.
Conf Proc IEEE Eng Med Biol Soc., 2009:224-7 (2009)
The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson's disease.
J. Neurol. Neurosurg. Psychiatr., Feb;81(2):171-6 (2010)
Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study.
Clin Neuropharmacol., 32(6):305-10 (2009 Nov-Dec)
Reduced performance in balance, walking and turning tasks is associated with increased neck tone in Parkinson's disease.
Exp. Neurol., Oct;219(2):430-8 (2009)
Teaching program for the Unified Dyskinesia Rating Scale.
Mov. Disord., Jul;24(9):1296-8 (2009)
Knee trembling during freezing of gait represents multiple anticipatory postural adjustments.
Exp. Neurol., Feb;215(2):334-41 (2009)
The Unified Dyskinesia Rating Scale: presentation and clinimetric profile.
Mov. Disord., Dec;23(16):2398-403 (2008)
Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.
Clin Neuropharmacol., 32(2):97-102 (2009 Mar-Apr)
Pharmacokinetics and pharmacodynamics of levodopa.
Mov. Disord., 23 Suppl 3:S580-4 (2008)
Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.
Mov. Disord., Oct;23(13):1860-6 (2008)
Genetic association between alpha-synuclein and idiopathic Parkinson's disease.
Am. J. Med. Genet. B Neuropsychiatr. Genet., Oct;147B(7):1222-30 (2008)
Treatment of Parkinson's disease with trophic factors.
Neurotherapeutics., Apr;5(2):270-80 (2008)
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.
Am. J. Clin. Pathol., Apr;129(4):526-9 (2008)
Control of medically refractory restless legs syndrome with intrathecal morphine: case report.
Neurosurgery., Jan;62(1):E263; discussion E263 (2008)
Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study.
Arch. Neurol., Feb;65(2):193-8 (2008)
Exploring gene-environment interactions in Parkinson's disease.
Hum. Genet., Apr;123(3):257-65 (2008)
Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease.
Eur. J. Neurol., Feb;15(2):134-9 (2008)
Disease progression, drug action and Parkinson's disease: why time cannot be ignored.
Eur. J. Clin. Pharmacol., Feb;64(2):207-16 (2008)
Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.
Mov. Disord., Jan;23(1):88-95 (2008)
Low doses of apomorphine transiently reduce locomotor activity in MPTP-treated mice.
Neurosci. Lett., Nov;428(2-3):64-7 (2007)
Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease.
Ann. Neurol., Aug;62(2):137-44 (2007)
Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Arch. Neurol., Mar;64(3):319-23 (2007)
Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.
Pharm. Res., Apr;24(4):791-802 (2007)
Joubert syndrome surviving to adulthood associated with a progressive movement disorder.
Mov. Disord., Jan;22(2):262-5 (2007)
Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study.
Lancet Neurol., Nov;5(11):917-23 (2006)
LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago.
Am. J. Hum. Genet., Oct;79(4):752-8 (2006)
Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
Mov. Disord., Jan;22(1):1-9 (2007)
An alternative clinical postural stability test for patients with Parkinson's disease.
J. Neurol., Nov;253(11):1404-13 (2006)
OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease.
Mov. Disord., Sep;21(9):1487-90 (2006)
Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
Neurology., May;66(10):1611-2; author reply 1611-2 (2006)
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
J Pharmacokinet Pharmacodyn., Jun;33(3):281-311 (2006)
GDNF in treatment of Parkinson's disease: response to editorial.
Lancet Neurol., Mar;5(3):200-2 (2006)
Multiple balance tests improve the assessment of postural stability in subjects with Parkinson's disease.
J. Neurol. Neurosurg. Psychiatr., Mar;77(3):322-6 (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
Ann. Neurol., Mar;59(3):459-66 (2006)
Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.
J Pharmacokinet Pharmacodyn., Aug;32(3-4):459-84 (2005)
Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.
J Pharmacokinet Pharmacodyn., Aug;32(3-4):307-31 (2005)
Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics.
Mov. Disord., Apr;21(4):519-23 (2006)
Clinical practice. Diagnosis and initial management of Parkinson's disease.
N. Engl. J. Med., Sep;353(10):1021-7 (2005)
Can stooped posture explain multidirectional postural instability in patients with Parkinson's disease?
Exp Brain Res., Sep;166(1):78-88 (2005)
Short-term paroxetine treatment does not alter the motor response to levodopa in PD.
Neurology., May;64(10):1797-8 (2005)
Direction-specific postural instability in subjects with Parkinson's disease.
Exp. Neurol., Jun;193(2):504-21 (2005)
Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism.
BMC Neurol., Feb;5(1):4 (2005)
Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.
J Pharmacokinet Pharmacodyn., Jun;31(3):243-68 (2004)
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2).
Mov. Disord., Jun;19(6):622-9 (2004)
The dopamine transporter: importance in Parkinson's disease.
Ann. Neurol., Jun;55(6):766-73 (2004)
Lancet., May;363(9423):1783-93 (2004)
Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease.
Exp. Neurol., Nov;184(1):9-13 (2003)
Family caregiving: a neglected and hidden part of health care delivery.
Neurology., Nov;51(5):1245-6 (1998)
Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.
Lancet., Apr;351(9111):1221-2 (1998)
Levodopa in human breast milk: clinical implications.
Neurology., Jun;50(6):1920-1 (1998)
Mood response to levodopa infusion in early Parkinson's disease.
Neurology., Jun;50(6):1890-2 (1998)
Catechol O-methyltransferase inhibition and the treatment of Parkinson's disease.
Adv. Pharmacol., 42:331-4 (1998)
Short- and long-duration responses to levodopa during the first year of levodopa therapy.
Ann. Neurol., Sep;42(3):349-55 (1997)
Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
Mov. Disord., May;12(3):285-92 (1997)
The response to levodopa in Parkinson's disease: imposing pharmacological law and order.
Ann. Neurol., May;39(5):561-73 (1996)
Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
Clin Neuropharmacol., Feb;19(1):59-64 (1996)
Dr. John Nutt M